全脑放疗联合靶向药物与单独全脑放疗治疗非小细胞肺癌脑转移疗效及安全性的Meta分析

发布时间：2018-09-12 05:13

【摘要】：目的采用Meta分析比较全脑放疗(WBRT)联合靶向药物与单用WBRT在非小细胞肺癌(NSCLC)脑转移瘤患者治疗中的疗效和安全性。方法计算机检索Pubmed、Embase、中国知网、万方数据库中有关WBRT联合靶向药物治疗NSCLC脑转移的文献,检索时间均从建库至2016年5月。通过纽卡斯尔-渥太华量表(NOS)对文献进行质量评价,采用优势比(OR)及其95%可信区间合并效应量,采用Rev Man5.2软件进行数据分析。结果最终纳入15篇研究文献,共计1 084例患者。结果显示:联合治疗组疾病控制率(OR:3.09,95%CI 2.11~4.54,P0.00001)、1年生存率(OR:2.55,95%CI 1.84~3.54,P0.00001)均高于单纯放疗组,差异具有明显统计学意义;安全性方面,联合治疗组皮疹发生率高于单纯放疗组(OR:9.10,95%CI 2.89~28.66,P=0.0002),但均属于Ⅰ~Ⅱ度不良反应,经对症处理后可缓解,其余不良反应如腹泻、恶心呕吐、乏力、骨髓抑制、呼吸困难两组比较均无统计学意义(P0.05)。结论WBRT联合靶向药物治疗NSCLC脑转移瘤明显优于单纯WBRT放疗,不良反应亦无明显增加。
[Abstract]:Objective to compare the efficacy and safety of global brain radiotherapy (WBRT) combined with targeted drugs and WBRT alone in the treatment of (NSCLC) brain metastases from non-small cell lung cancer (NSCLC) by Meta analysis. Methods the literatures about the treatment of brain metastasis of NSCLC with WBRT combined with targeted drugs in Wanfang database were searched by computer. The retrieval time was from the establishment of the database to May 2016. The quality of literature was evaluated by Newcastle Ottawa scale (NOS). The dominance ratio (OR) and its 95% confidence interval (CI) combined effect were used to analyze the data by Rev Man5.2 software. Results A total of 1 084 patients were included in 15 articles. The results showed that the disease control rate (OR:3.09,95%CI 2.114.54) and the 1-year survival rate (OR:2.55,95%CI 1.84 + 3.54% P0.00001) in the combined treatment group were significantly higher than those in the radiotherapy alone group (P 0.00001), and the difference was statistically significant. The incidence of skin rash in the combined treatment group was higher than that in the radiotherapy alone group (OR:9.10,95%CI 2.89 ~ 28.66 P0. 0002), but all of them belonged to 鈪，

本文编号：2238012